Better blood cancer treatments
As part of our commitment to deliver more effective treatments in the shortest possible time for blood cancer patients, we have partnered with The University of Queensland Diamantina Institute (UQDI) and the Queensland Government to establish a new research position at the Translational Research Institute (TRI) in Brisbane.
Haematologist Professor Maher Gandhi has been appointed as our Chair in Blood Cancer Research, based at UQDI at the TRI, tasked with establishing and coordinating a world-leading research program in near-patient research of blood cancers.
Near-patient research involves clinicians treating patients in close proximity to their research laboratories.
Improved diagnosis and prevention
Professor Gandhi said his research would aim to understand the basis of blood cancer.
“I will seek to devise less toxic and more effective treatments, to establish new biomarkers which will help determine the most effective treatment strategies, to monitor response and relapse, and to understand the development of blood cancers,” he said.
He said the new research program could lead to improved diagnosis, treatment, cure and prevention for blood cancer patients.
Our CEO Bill Petch said the Foundation’s commitment of $1 million over five years was the next step in our plan to expand investment across the research spectrum to maximise benefits for patients.
“With one Australian diagnosed with a blood cancer every 46 minutes and someone losing their life to blood cancer every two hours, we’re committed to finding the best possible treatment options for patients,” Mr Petch said.
“As part of our five-year strategic plan for research, the Foundation will not only continue investments in basic science, we will be steering research closer to patient bedsides by investing more in projects that transform scientific discoveries from the lab into meaningful health outcomes. This includes clinical trials as well as translational research.”
Mr Petch said the Foundation looked forward to working closely with Professor Gandhi and UQ Diamantina Institute at TRI, along with its other research partners across the state, to deliver better patient outcomes.
The University of Queensland Diamantina Institute (UQDI) is a research facility and partner of the Translational Research Institute (TRI) located beside the Princess Alexandra Hospital in Brisbane. Research activities are focused on cancer, immunology and genomic medicine.
The Leukaemia Foundation is celebrating Medical Research Week, running from June 2 to June 10. Take action today and help the Leukaemia Foundation keep the momentum going to find better blood cancer treatments, please click here.
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.